Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Sell Aptamer Group (APTA) by Steve Moore in ShareProphets
- Sell Windar Photonics (WPHO) by Steve Moore in ShareProphets
- Avoid URU Metals Ltd. (DI) (URU) by Nigel Somerville in ShareProphets
- Sell Videndum (VID) by Steve Moore in ShareProphets
- Avoid PZ Cussons (PZC) by Steve Moore in ShareProphets
- Avoid TT Electronics (TTG) by Steve Moore in ShareProphets
- Sell Microsaic Systems (MSYS) by Steve Moore in ShareProphets
- Sell The Revel Collective (TRC) by Steve Moore in ShareProphets
- Buy KEFI Gold and Copper (KEFI) by Hot Stock Rockets in ShareProphets
- Avoid Naked Wines (WINE) by Steve Moore in ShareProphets
- Sell Mirriad Advertising (MIRI) by Steve Moore in ShareProphets
- Hold M&G (MNG) by Cliff D'Arcy in The Motley Fool
- Buy Safestore Holdings (SAFE) by Zaven Boyrazian in The Motley Fool
- Buy Altona Rare Earths (REE) by Hot Stock Rockets in ShareProphets
- Avoid Surgical Innovations Group (SUN) by Steve Moore in ShareProphets
- Outperform OSB Group (OSB) by RBC Capital
- Buy Diageo (DGE) by Harvey Jones in The Motley Fool
- Watch Nexteq (NXQ) by Steve Moore in ShareProphets
- Overweight Jet2 (JET2) by Barclays
- Outperform IntegraFin Holding (IHP) by RBC Capital
BiVictriX Therapeutics (BVX) Share Price
Health Care Sector
NOTE: This is based on 0 open tips for BiVictriX Therapeutics (BVX)
| Latest Bid : 8.50p | Latest Ask : 9.50p |
| High Today : 9.38p | Low Today : 8.50p |
| This Years High : 14.00p | This Years Low : 7.50p |
| Volume : 1,004,992 | MKT Cap : £8.2M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
BiVictriX Therapeutics (BVX) Overview
BVX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce cancer selective therapeutics. The Bi-Cygni® technology has been developed to exploit this concept and expedite the development of bispecific therapeutics with an improved therapeutic index. Based on BVX's work to date, these ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs. The main country of operation is in the UK.BiVictriX Therapeutics (BVX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 8.50p | Latest Ask : 9.50p |
| High Today : 9.38p | Low Today : 8.50p |
| This Years High : 14.00p | This Years Low : 7.50p |
| Volume : 1,004,992 | MKT Cap : £8.2M |
BiVictriX Therapeutics Overview
BVX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce cancer selective therapeutics. The Bi-Cygni® technology has been developed to exploit this concept and expedite the development of bispecific therapeutics with an improved therapeutic index. Based on BVX's work to date, these ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs. The main country of operation is in the UK.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.